NASDAQ:ANAB - AnaptysBio Stock Price, Forecast & News

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

AnaptysBio Inc (NASDAQ:ANAB) announced its quarterly earnings data on Friday, November, 8th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.09) by $0.06. During the same period last year, the firm posted ($0.66) earnings per share. View AnaptysBio's Earnings History.

AnaptysBio is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for AnaptysBio.

9 brokerages have issued 1-year target prices for AnaptysBio's shares. Their forecasts range from $12.00 to $140.00. On average, they anticipate AnaptysBio's stock price to reach $79.25 in the next twelve months. This suggests a possible upside of 410.0% from the stock's current price. View Analyst Price Targets for AnaptysBio.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AnaptysBio.

Headlines about ANAB stock have been trending very negative this week, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AnaptysBio earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for AnaptysBio.

AnaptysBio saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 3,970,000 shares, an increase of 14.7% from the December 15th total of 3,460,000 shares. Based on an average trading volume of 941,900 shares, the days-to-cover ratio is currently 4.2 days. Currently, 16.3% of the company's stock are sold short. View AnaptysBio's Current Options Chain.

Some companies that are related to AnaptysBio include Akcea Therapeutics (AKCA), Ligand Pharmaceuticals (LGND), Alder Biopharmaceuticals (ALDR), Esperion Therapeutics (ESPR), Amneal Pharmaceuticals (AMRX), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Innoviva (INVA), Intra-Cellular Therapies (ITCI), Endo International (ENDP), Dicerna Pharmaceuticals (DRNA), TG Therapeutics (TGTX), BELLUS Health (BLUSF), Nabriva Therapeutics (NBRV) and Madrigal Pharmaceuticals (MDGL).

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include Editas Medicine (EDIT), Baidu (BIDU), Alibaba Group (BABA), Baozun (BZUN), IQIYI (IQ), Momo (MOMO), NVIDIA (NVDA), AbbVie (ABBV), bluebird bio (BLUE) and Illumina (ILMN).

(ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANAB stock can currently be purchased for approximately $15.54.

AnaptysBio has a market capitalization of $421.65 million and generates $5 million in revenue each year. The biotechnology company earns $-61,660,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. AnaptysBio employs 78 workers across the globe.View Additional Information About AnaptysBio.

The official website for AnaptysBio is http://www.anaptysbio.com/.

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]